Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03526887
Title Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Spanish Lung Cancer Group

lung non-squamous non-small cell carcinoma

lung squamous cell carcinoma

lung non-small cell carcinoma



Age Groups: adult | senior
Covered Countries ESP

Additional content available in CKB BOOST